vinblastine / Generic mfg. - LARVOL DELTA

Preservation of gonadal function following chemotherapy protocols with acvd and acvd-BV in adults diagnosed with advanced-stage Hodgkin lymphoma: A single center experience. (ASH 2025) - "ACVD (Adriamycin 25 mg/m², Cyclophosphamide 400 mg/m², Vinblastine 6 mg/m² (max 10 mg) and Dacarbazine 375 mg/m²) is a modified chemotherapy regimen from ABVD given IV on day 1 and day 15 and repeated every 28 days for 6 cycles, replacing bleomycin with low dose cyclophosphamide to further optimize efficacy and reduce pulmonary and gonadal toxicity. Brentuximab vedotin is added to ACVD (ACVD-BV) in those cases of positive PET following 2 cycles of ACVD...Sperm banking was performed for 18/34 (53%) males before starting chemotherapy, and only 3/22 (13.617%) females received leuprorelin (GnRH agonist) during the chemotherapy... This study shows a favorable advantage of ACVD /ACVD-BV chemotherapy in treating advanced-stage HL where majority of cases gained their gonadal functions. However, limitations include retrospective design, missing baseline gonadal function evaluation, particularly semen analyses, and inconsistent hormone level documentation...."

Clinical • Metastases • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma

Efficacy and safety of nivolumab-based therapies in first-line and Relapsed/Refractory Hodgkin lymphoma (ASH 2025) - "Combination regimens involving nivolumab with agents such as brentuximab vedotin (BV), AVD (adriamycin, vinblastine, dacarbazine) combination chemotherapy, and novel immunomodulators have shown promising activity. In relapsed or refractory CHL, nivolumab-based regimens are highly effective, producing durable responses and favorable survival outcomes, especially when combined with chemotherapy or antibody-drug conjugates such as BV. Although AEs are more common in multi-agent regimens, the safety profile remains acceptable. Nivolumab's role as a salvage or consolidation therapy is supported, given its relatively lower efficacy in the first-line therapeutic context."

Clinical • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma

Do patients with classic Hodgkin's lymphoma treated with ABVD in low-middle income countries have a higher risk of neutropenia/febrile neutropenia without G-CSF support? a single-center retrospective study (ASH 2025) - "Introduction: Patients with Hodgkin lymphoma (cHL) who receive adriamycin, bleomycin, vinblastine, anddacarbazine (ABVD) chemotherapy commonly experience neutropenia; however, the incidence of febrileneutropenia is rare. The omission of G-CSF support in patients treated with ABVD appears to be both safe andresource-saving in LMIC. Despite the observed higher incidence of stage IV disease and B symptoms—indicative of delays in diagnosis and referral and suggesting a more clinically challenging population—febrile neutropenia was infrequent and did not adversely affect progression-free survival (PFS) or overallsurvival (OS). To our knowledge, this study represents the largest cohort of classic Hodgkin lymphoma(cHL) patients from low- and middle-income countries (LMIC) assessed for neutropenia and febrileneutropenia following ABVD treatment."

Retrospective data • Classical Hodgkin Lymphoma • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Neutropenia

Precise-HL trial: Personalized reduction of chemotherapy intensity through ctdna evaluation in advanced Hodgkin lymphoma (ASH 2025) - P2 | "First patient was enrolled in February 2025.Patients will receive the combination of nivolumab (240 mg IV), doxorubicin (25 mg/m2 IV), vinblastine (6mg/m2 IV) dacarbazine (375 mg/m2 IV) on days 1 and 15 of 28-day cycles.Blood samples for PhasED-Seq testing at baseline and post cycle 2 will be sent to Foresight Diagnosticsfor rapid processing (estimated turn-around time 10-14 days). Key eligibility criteria include untreated stage 3 or 4 classic Hodgkin lymphoma, age 18+, measurabledisease per Lugano criteria, and adequate marrow, renal, and hepatic function. Key exclusion criteriainclude current or prior autoimmune disease except vitiligo or thyroid disease on stable replacementdoses, active cardiac disease or ejection fraction < 50%, prior malignancies within 2 years, and pregnantor nursing women."

Circulating tumor DNA • IO biomarker • Metastases • Classical Hodgkin Lymphoma • Dermatology • Endocrine Disorders • Heart Failure • Hematological Malignancies • Hodgkin Lymphoma • Immunology • Lymphoma • Vitiligo

Targeted immunotherapy in children, adolescents, and young adults (CAYA) with newly diagnosed classical Hodgkin lymphoma: A single center experience (ASH 2025) - "Ourapproach combines the use of the antibody-drug conjugat,e brentuximab vedotin (Bv), targeting Reed-Sternberg (RS) cells, along with the anti-CD20 antibody rituximab (RTX) and checkpoint inhibitornivolumab (N) targeting the TME, added to risk-adapted chemotherapy in newly diagnosed CAYA cHLpatients. This chemoimmunotherapy approach allows for anthracycline dose reduction and radiationsparing in intermediate and high-risk patients.Our early cHL clinical trial enrolled patients 3-39yr old who received a backbone of brentuximab vedotin,doxorubicin, vinblastine, dacarbazine, and rituximab (Bv-AVD-R) given on Day 1, 2 and Day 15,16 of eachcycle...The addition of immunotherapy to a reduced-intensity chemotherapy backbone is safe, effective and welltolerated. Targeting the HRS cell as well as the TME via the PD1/PD-L1 axis is a promising approach inCAYA with cHL and allows for reduction in both anthracycline and radiation exposure. This is important inlimiting short- and..."

Clinical • Classical Hodgkin Lymphoma • Febrile Neutropenia • Hodgkin Lymphoma • Lymphoma • Mucositis • Neutropenia

Brentuximab vedotin (Bv)+AVD efficacy is influenced by interim PET, age, ECOG performance status and CIRS-g in previously untreated patients with stage IV classical Hodgkin lymphoma: An Italian real-life multicentric study (ASH 2025) - "Introduction: In Italy, Brentuximab vedotin (Bv) with AVD (adriamycin, vinblastine, dacarbazine) receivedapproval for the first-line treatment of stage IV classical Hodgkin lymphoma (cHL) in September 2021,with no upper age restriction. In a real-life population of stage IV adult cHL, the Bv+AVD regimen efficacy on PFS isinfluenced by TTM, interim PET DS4-5 (that also impacted on OS), age, ECOG-PS and CIRS-G. The Frailtyscore appears useful to select who can benefit less from Bv-AVD and could represent a tool to betterstratify patients in the era of novel standards for the first-line therapy of advanced stage cHL."

Clinical • Metastases • Classical Hodgkin Lymphoma • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Immunology • Infectious Disease • Lymphoma • Neutropenia

Nivolumab with doxorubicin, vinblastine, and dacarbazine (NAVD) in older adults with classic Hodgkin lymphoma: Do S1826 results hold up in the real world? (ASH 2025) - "Overall, 15% pts required steroids withresolution of IrAEs in 56% cases, 30% (n=7) pts required continued therapy (levothyroxine in 4 pts,steroids in 3 pts, medical tx for heart failure in 1 pt). In this largest RWS cohort of OAs treated with NAVD we showed comparable response rates, AEs and 1-year survival outcomes to those in the pivotal S1826 trial. Notably, rates of ≥G3 AEs including infections,neuropathy and IrAEs remained low and manageable. Although survival significantly improved withNAVD compared to historical data, outcomes of OAs remained inferior compared to pts <60 yrs."

Clinical • Real-world • Real-world evidence • Cardiovascular • Classical Hodgkin Lymphoma • Congestive Heart Failure • Endocrine Disorders • Febrile Neutropenia • Gastroenterology • Gastrointestinal Disorder • Heart Failure • Hematological Disorders • Hematological Malignancies • Hepatology • Hodgkin Lymphoma • Immunology • Infectious Disease • Inflammatory Arthritis • Lymphoma • Nephrology • Neutropenia • Pneumonia • Renal Disease • Rheumatology • Sarcoidosis

Incidence of severe chemotherapy-associated nausea and vomiting with brentuximab vedotin and AVD in comparison with ABVD using standard anti-emetic prophylaxis (ASH 2025) - "The BV-AVD (brentuximab vedotin-doxorubicin, vinblastine, dacarbazine) regimen for cHL improves overall survival in advanced stagedisease in comparison to ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine), however, thecomparative incidence of CINV with BV-AVD relative to ABVD is not well described...All patientsreceived anti-emetic prophylaxis of palonosetron and dexamethasone with the first cycle of treatment.The median age of diagnosis for the ABVD group (30 years) and the BV-AVD group (34 years) were similar(p=0.48)... We observed a higher incidence of severe nausea in patients with cHL who were treatedwith BV-AVD as compared to ABVD, when receiving the same standard anti-emetic prophylaxis. Patientstreated with BV-AVD also experienced more hospitalizations for CINV, combined hospitalizations or EDvisits for CINV, and significant weight loss due to CINV. The results of this study suggest that patientsreceiving BV-AVD for cHL may benefit from more intensive..."

Chemotherapy-Induced Nausea and Vomiting • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma

Low-dose nivolumab combined with AVD chemotherapy (Nivo40-AVD) for advanced stage classic Hodgkin lymphoma (ASH 2025) - P2 | "Recently published SWOG S1826 trial demonstrated high efficacy and low toxicity of first-line nivolumabcombined with adriamycin, vinblastine, dacarbazine (N-AVD) in newly-diagnosed advanced stage classicHodgkin lymphoma (cHL) with the two-year progression-free survival (PFS) of 92%. In patientsachieving only partial metabolic response after 6 cycles (Deauville score ≥ 4) radiation therapy is allowed.The primary endpoint is 2-year PFS. Secondary endpoints include ORR and CR rates, 2-year overallsurvival, and adverse events rate."

IO biomarker • Metastases • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Immunology • Infectious Disease • Lymphoma

Real-world clinical outcomes with novel agent combination therapies for the frontline treatment of pediatric and adult advanced-stage Hodgkin lymphoma (ASH 2025) - "Introduction:Brentuximab vedotin (BV) and nivolumab (N) have resulted in significant progress in the treatment ofadvanced-stage Hodgkin lymphoma (AS-HL). The SWOG 1826 trial demonstrated a progression-freesurvival (PFS) and safety benefit with frontline N-AVD (doxorubicin, vinblastine, and dacarbazine)compared to BV-AVD; however, real-world data are limited...This large real-world multicenter study demonstrates that response rates and 1-yr survival outcomes withN-AVD and BV-AVD are similar to the published SWOG 1826 trial (N-AVD vs BV-AVD: 1-yr PFS: 94% vs 86%,Herrera et al. 2024). Increased cardiovascular AEs, dose reductions/omissions and neuropathy with BV-AVD indicate better tolerability with N-AVD; however, the higher rate of febrile neutropenia andinfections in comparison to SWOG 1826 in N-AVD pts suggests that growth factor prophylaxis may bebeneficial in select high-risk subgroups."

Clinical • Clinical data • Combination therapy • Metastases • Real-world • Real-world evidence • Cardiovascular • Febrile Neutropenia • Hematological Malignancies • Hodgkin Lymphoma • Infectious Disease • Lymphoma • Neutropenia • Pediatrics • Septic Shock • Thrombosis

Interim and end-of-treatment FDG-PET demonstrate limited ability to predict 3-year progression-free survival with nivolumab-AVD in first-line treatment of advanced stage Hodgkin lymphoma: Imaging sub-analysis of Phase 3 S1826 study (ASH 2025) - "Introduction: The primary analysis of the randomized Phase 3 S1826 study in patients (pts) withpreviously untreated, advanced stage Hodgkin lymphoma (HL) showed a marked improvement in 1- and2-year progression-free survival (PFS) with nivolumab, doxorubicin, vinblastine, dacarbazine (Nivo-AVD)compared to brentuximab vedotin (BV)-AVD (Herrera, NEJM, 2024). Like prior studies in advanced stage HL, both iPET and EoT PET showed statisticallysignificant differences in 3-year PFS for PET-neg vs. PET-pos, however EoT PET results were more clinicallysignificant. Importantly, 84% of iPET-pos pts and 68% of EOT PET-pos pts treated with N-AVD remainprogression-free at 3 yrs, suggesting significant limitations of PET Lugano criteria when applied to currenttherapies in HL and emphasizing the need to continue exploring new response assessment tools such asctDNA."

Clinical • FDG PET • Metastases • P3 data • P3 data: top line • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma

A real-world analysis of safety and outcomes with first line nivolumab in combination with doxorubicin, vinblastine, and dacarbazine (NAVD) in patients with classic Hodgkin lymphoma (cHL) – a multicenter cohort study (ASH 2025) - "S1826 demonstrated a 1-year progression free survival (PFS) of 94% forNAVD compared to 86% for brentuximab vedotin-AVD, which remained durable at 2 years (Herrera et al,NEJM 2024)...Among all pts, 14.4% (n=45) requiredsystemic steroids at any time (intravenous in 4.1%), 3.2% (n=10) require ongoingsteroids/immunosuppression and 8.3% other therapy for an irAE (n=23 levothyroxine, n=1 hemodialysis,n=1 heart failure tx, n=1 insulin).Among all pts, 265 (85%) had an interim PET-CT after 2-4 cycles...Pts treated with NAVD in a large RWS showed comparable response rates and 1-year survival outcomesto those in the pivotal S1826 trial. Most AEs were similar and grade 1-2, but close monitoring of irAEs isnecessary given the potential long-term toxicity of checkpoint inhibitors and potential for ≥G3 irAEs(7.5%) in this young patient population. Our data supports the use of NAVD for 1L advanced stage cHL."

Clinical • Combination therapy • Real-world • Real-world evidence • Cardiovascular • Classical Hodgkin Lymphoma • Congestive Heart Failure • Diabetes • Endocrine Disorders • Febrile Neutropenia • Gastroenterology • Gastrointestinal Disorder • Heart Failure • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Immunology • Infectious Disease • Inflammation • Inflammatory Arthritis • Lymphoma • Metabolic Disorders • Nephrology • Neutropenia • Pancreatitis • Renal Disease • Rheumatology

The influence of age on patient-reported outcomes (PROs) endpoints on the S1826 cross-network Phase III trial of advanced-stage, classic Hodgkin lymphoma (cHL) (ASH 2025) - "We assessed PROs in S1826, a trial showingthat nivolumab plus doxorubicin, vinblastine, and dacarbazine (N+AVD) resulted in longer progression-free survival compared to brentuximab vedotin plus AVD (BV+AVD). Trial results support the feasibility ofserial collection of PROs, as indicated by high response rates, despite participants' advanced stagedisease and broad institutional participation. Future analyses will address the planned 3-year outcomesas well as formal evaluation of missing data."

Clinical • Metastases • P3 data • Patient reported outcomes • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma

Clinical prognostication in the SWOG 1826 randomized clinical trial of nivolumab-AVD versus brentuximab-AVD: Performance of the advanced-stage Hodgkin lymphoma international prognostic index (A-HIPI) (ASH 2025) - "The phase 3 randomized SWOG S1826 study, the largest National Clinical Trials Network study of AS cHL,compared nivolumab with doxorubicin, vinblastine, and dacarbazine (N+AVD) with brentuximab vedotinwith doxorubicin, vinblastine, and dacarbazine (BV+AVD) in pts 12 yrs or older with AS newly diagnosedcHL. This refined prediction model, which leverages continuous datavalues, is poised to serve as the new standard for risk stratification for adults with AS cHL. Funding NIH/NCI grant awards U10CA180888, U10CA180819, R01CA262265-04"

Clinical • Metastases • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma

3-year follow-up of the S1826 study confirms improved progression-free survival with nivolumab-AVD compared to brentuximab vedotin-AVD in advanced stage classic Hodgkin lymphoma (ASH 2025) - "Introduction: The randomized phase 3 S1826 study demonstrated that, in adolescent and adult patients(pts) with previously untreated advanced stage (AS) classic Hodgkin lymphoma (cHL), PD-1 blockade withnivolumab in combination with doxorubicin, vinblastine, and dacarbazine (N-AVD) prolongedprogression-free survival (PFS) compared with standard brentuximab vedotin (BV) combined with AVD ata median follow-up of 2 years. The benefit of N-AVD compared to BV-AVD in adolescent and adult pts with AS cHL issustained with 3y follow-up, including all pre-specified age, stage, and IPS risk subgroups. This updatedemonstrates the durability of remissions with N-AVD over time without any new safety signals, andenables benchmarking with other modern cHL trials. Follow-up will continue to evaluate for latetoxicities, OS, and PROs."

Metastases • Classical Hodgkin Lymphoma • Genetic Disorders • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Skin Cancer • Solid Tumor

Advances in the Diagnosis and Management of Pediatric Langerhans Cell Histiocytosis and Rosai-Dorfman Disease: Therapies, Biomarkers, and Response Assessment (ASH 2025) - "Eckstein will discuss frontline and salvage treatment strategies, including the use of vinblastine, cytarabine, clofarabine, and targeted agents such as BRAF and MEK inhibitors, as well as practical approaches to monitoring disease response and managing CNS involvement. Real-world challenges in treating refractory or relapsed disease will be addressed, alongside strategies for integrating molecular diagnostics and emerging therapies into routine practice. Attendees will gain actionable insights into optimizing outcomes for children and adults with these rare histiocytic disorders."

Biomarker • Clinical • Langerhans Cell Histiocytosis • Pediatrics • Rare Diseases

Down the Rabbit Hole: An Update on Histiocytic Disorders (ASH 2025) - "She will outline current guidelines for risk stratification, discuss frontline and salvage therapy options — including vinblastine, cytarabine, clofarabine, and targeted therapies — and address the role of MAPK and other molecular drivers in therapeutic decision-making. Drawing from real-world cases, he will highlight diagnostic tools, prognostic scoring systems, and the evolving landscape of personalized treatment. Emphasis will be placed on how hematologists can optimize their approach to HLH in high-risk inpatient settings and in collaboration with multidisciplinary teams.Attendees will gain practical, case-driven insights into the evolving classification, molecular landscape, and treatment strategies for histiocytic neoplasms across diverse clinical contexts."

Preclinical • Hematological Disorders • Hemophagocytic lymphohistiocytosis • Immunology • Infectious Disease • Langerhans Cell Histiocytosis • Rare Diseases • Septic Shock

Profound hematologic instability in consanguinity-associated familial hemophagocytic lymphohistiocytosis: a pediatric case report. (PubMed, Ann Med Surg (Lond)) - "Patient was referred to the oncology department and started on initial chemotherapy with vinblastine, prednisolone, and mercaptopurine and continuation chemotherapy therapy with vinblastine. Advances in genetic testing and treatment modalities are critical for improving outcomes and long-term prognosis in FHL. Continued research is essential to refine diagnostic criteria and therapeutic strategies for optimal patient care."

Journal • Cough • Hematological Disorders • Hemophagocytic lymphohistiocytosis • Immunology • Infectious Disease • Inflammation • Leukopenia • Oncology • Pediatrics • Pneumonia • Rare Diseases • Respiratory Diseases • Thrombocytopenia

Relapsed Classical Hodgkin Lymphoma in Pregnancy in Two Patients Managed With a Multidisciplinary Approach. (PubMed, Case Rep Oncol Med) - "The first patient with Stage IIIB cHL achieved a complete response (CR) with ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) prior to pregnancy but relapsed at 10 weeks of gestation. After delivery, both patients underwent ICE (ifosfamide, carboplatin, and etoposide), followed by consolidation with autologous hematopoietic cell transplantation (auto-HCT). These cases highlight the balance needed to maintain control of disease to allow a safe and uneventful pregnancy."

Journal • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology • Transplantation

Nivo40-AVD for Advanced Classic Hodgkin Lymphoma (clinicaltrials.gov) - P2 | N=54 | Recruiting | Sponsor: National Medical Research Radiological Centre of the Ministry of Health of Russia | Trial completion date: Jan 2032 ➔ Jan 2029 | Trial primary completion date: Jan 2029 ➔ Jan 2028

Trial completion date • Trial primary completion date • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology

A prognostic model for breast cancer survival based on PCD and m6A gene interactions. (PubMed, Front Immunol) - "A key finding from drug sensitivity analysis was that the high-risk group exhibited significantly increased sensitivity to several drugs, including CCT018159, rapamycin, vinblastine, metformin, and roscovitine. Moreover, the expression levels of SESN3, CRIP1, DPP4 and PIK3CA were significantly upregulated in breast cancer samples compared to control samples. This study constructed a risk model based on seven prognostic genes, offering new potential strategies for breast cancer therapy."

Biomarker • Journal • Breast Cancer • Herpes Simplex • Infectious Disease • Oncology • Solid Tumor • ANXA5 • CRIP1 • DAXX • MYD88 • PIK3CA

Comprehensive Review of Analytical Approaches for Vinblastine and Vincristine in Cancer Research. (PubMed, Biomed Chromatogr) - "Key analytical considerations include light sensitivity, pH and temperature control, and matrix interferences. Overall, recent methodological advancements enable reliable quantification of VBL and VCR, supporting safer clinical application, toxicity monitoring, and environmental surveillance."

Journal • Review • Hematological Disorders • Hematological Malignancies • Oncology • Solid Tumor

A Multicenter Retrospective Study of Avelumab First-Line Maintenance and Subsequent Therapies for Locally Advanced and Metastatic Urothelial Carcinoma: Subgroup Analysis of First-Line Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, and Gemcitabine Plus Cisplatin in the Japan AVElumab MAintenance and Continuous Treatment Study (JAVEMACS). (PubMed, Curr Oncol) - "Second-line treatments included EV (64.3% ddMVAC; 64.5% GC), pembrolizumab (21.4% ddMVAC; 8.3% GC), and PBC (14.3% ddMVAC and 21.5% GC). This real-world data from patients with aUC in Japan showed consistent OS patterns with avelumab maintenance across treatment subgroups vs. the overall population despite their inherent heterogeneity. Although patients were not resistant to PBC, 2L EV was more common than 2L PBC."

Journal • Retrospective data • Oncology • Solid Tumor • Urothelial Cancer

A prognostic model derived from PANoptosis-associated subtypes unveils immunological features and therapeutic vulnerabilities in cervical cancer. (PubMed, Discov Oncol) - "This study establishes a PANoptosis-derived prognostic model with moderate but consistent prognostic utility across platforms, underscoring its potential research value. By linking PRGs to risk stratification and immune heterogeneity, the model provides insights into PANoptosis biology and supports future exploration of personalized immunotherapy in cervical cancer."

IO biomarker • Journal • Tumor mutational burden • Cervical Cancer • Oncology • Solid Tumor • BTLA • CCL19 • PLAAT4 • TMB

RARE CASE OF INFLAMMATORY MYOFIBROBLASTIC TUMOR (IMT) IN NEWBORN (CTOS 2025) - "Somatic disease germline comparator (SDGC) exome sequencing, RNA-sequencing, and RT-PCR demonstrated a LRRFIP1::ALK fusion. Given the inability to surgically resect the mass without substantial comorbidities, treatment was started with vinblastine/methotrexate. Lorlatinib was added after identification of the ALK fusion... We present the case of an infant with a prenatally diagnosed, unresectable neck mass, confirmed IMT with LRRFIP1::ALK fusion. Only a limited number of IMT cases diagnosed in the prenatal period have been described in the literature. This case is further characterized by the infant's complete response to treatment, highlighting the feasibility and effectiveness of personalized, targeted therapy in very young patients."

Clinical • Oncology • ALK • ALK1 • CD34 • LRRFIP1 • MUC4 • MYOD1 • Myogenin